The estimated Net Worth of Robert Scott Fishel is at least 143 千$ dollars as of 25 January 2021. Robert Fishel owns over 60,000 units of Opko Health Inc stock worth over 93,600$ and over the last 7 years he sold OPK stock worth over 0$. In addition, he makes 48,917$ as Independent Director at Opko Health Inc.
Robert has made over 11 trades of the Opko Health Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of OPK stock worth 162,000$ on 25 January 2021.
The largest trade he's ever made was exercising 60,000 units of Opko Health Inc stock on 25 January 2021 worth over 162,000$. On average, Robert trades about 11,206 units every 64 days since 2018. As of 25 January 2021 he still owns at least 60,000 units of Opko Health Inc stock.
You can see the complete history of Robert Fishel stock trades at the bottom of the page.
Dr. Robert Scott Fishel M.D. serves as Independent Director of the Company. Dr. Fishel serves as a director of several private companies. He is a director and founder of Florida Electrophysiology Associates, a premiere medical practice specializing in cardiac rhythm disorders, and has been the Chief Executive Officer and President since 1997, a director and senior managing partner of Renaissance Properties, a multi-faceted real estate development firm, since 1989, a director and founding partner of Catalyst Development Partners, a real estate development firm focused on multifamily acquisition and development opportunities, since 2009, a director and president of ALSAR Ltd Partnership since 1996, an investment partnership with investments in public equities, debt and derivatives, and a director, founder, and Chief Medical Officer of NewPace, Ltd., a company engaged in the research and development of medical equipment, including a novel implantable subcutaneous string defibrillator (ISSD) for preventing sudden cardiac death, since 2012. Dr. Fishel is director of cardiac electrophysiology at JFK Medical Center in West Palm Beach Florida and co-director of national electrophysiology research for the Hospital Corporation of America’s Cardiovascular Research Council. Dr. Fishel is an Affiliate Associate Professor of Medicine at the Charles E. Schmidt College of Medicine, Florida Atlantic University School of Medicine’s Division of Integrated Sciences.
As the Independent Director of Opko Health Inc, the total compensation of Robert Fishel at Opko Health Inc is 48,917$. There are 12 executives at Opko Health Inc getting paid more, with Phillip Frost having the highest compensation of 1,405,200$.
Robert Fishel is 58, he's been the Independent Director of Opko Health Inc since 2018. There are 18 older and 2 younger executives at Opko Health Inc. The oldest executive at Opko Health Inc is John Paganelli, 85, who is the Independent Director.
Robert's mailing address filed with the SEC is 4400, Biscayne Boulevard, Buena Vista, Miami, Miami-Dade County, Florida, 33137, United States.
Over the last 18 years, insiders at Opko Health Inc have traded over 862,245$ worth of Opko Health Inc stock and bought 128,867,460 units worth 425,265,065$ . The most active insiders traders include Phillip Md Et Al Frost Neva...、Phillip Md Et Al Frost Gamm...、Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of 142,696$. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth 127,000$.
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
Opko Health Inc executives and other stock owners filed with the SEC include: